JP2024041959A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041959A5
JP2024041959A5 JP2024005578A JP2024005578A JP2024041959A5 JP 2024041959 A5 JP2024041959 A5 JP 2024041959A5 JP 2024005578 A JP2024005578 A JP 2024005578A JP 2024005578 A JP2024005578 A JP 2024005578A JP 2024041959 A5 JP2024041959 A5 JP 2024041959A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
aryl
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024005578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024041959A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/064879 external-priority patent/WO2019118411A2/en
Application filed filed Critical
Publication of JP2024041959A publication Critical patent/JP2024041959A/ja
Publication of JP2024041959A5 publication Critical patent/JP2024041959A5/ja
Pending legal-status Critical Current

Links

JP2024005578A 2017-12-11 2024-01-17 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 Pending JP2024041959A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762597160P 2017-12-11 2017-12-11
US62/597,160 2017-12-11
PCT/US2018/064879 WO2019118411A2 (en) 2017-12-11 2018-12-11 Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
JP2020550062A JP7466455B2 (ja) 2017-12-11 2018-12-11 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020550062A Division JP7466455B2 (ja) 2017-12-11 2018-12-11 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2024041959A JP2024041959A (ja) 2024-03-27
JP2024041959A5 true JP2024041959A5 (https=) 2024-05-31

Family

ID=66819489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550062A Active JP7466455B2 (ja) 2017-12-11 2018-12-11 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法
JP2024005578A Pending JP2024041959A (ja) 2017-12-11 2024-01-17 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020550062A Active JP7466455B2 (ja) 2017-12-11 2018-12-11 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法

Country Status (13)

Country Link
US (1) US20190201541A1 (https=)
EP (1) EP3723763A4 (https=)
JP (2) JP7466455B2 (https=)
KR (1) KR20200117992A (https=)
CN (1) CN111787923A (https=)
AU (1) AU2018385599A1 (https=)
BR (1) BR112020011445A2 (https=)
CA (1) CA3082912A1 (https=)
EA (1) EA202091161A1 (https=)
IL (1) IL275190A (https=)
MX (1) MX2020006010A (https=)
SG (1) SG11202004579RA (https=)
WO (1) WO2019118411A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
CA3082912A1 (en) * 2017-12-11 2019-06-20 Triphase Accelerator U.S. Corporation Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
KR20220079576A (ko) 2019-10-04 2022-06-13 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd25 항체-메이탄신 접합체 및 이의 사용 방법
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
KR20230122008A (ko) * 2020-11-20 2023-08-22 알.피.쉐러 테크놀러지즈 엘엘씨 항체-약물 접합체를 위한 글리코시드 이중-절단 링커
EP4301415A4 (en) * 2021-03-03 2026-03-18 Scherer Technologies Llc R P Branched-Cell Networks for Antibody-Drug Conjugates and Their Methods of Use
WO2023009759A2 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
KR20240083175A (ko) * 2021-08-25 2024-06-11 알.피.쉐러 테크놀러지즈 엘엘씨 항체-약물-접합체를 사용하는 방법
AU2023268538A1 (en) * 2022-05-13 2024-11-21 Exelixis, Inc. 5t4 antibody-drug conjugates and uses thereof
AU2024292307A1 (en) * 2023-07-20 2026-01-29 Exelixis, Inc. Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof
WO2025019780A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses thereof
WO2025019776A2 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Interleukin-13 receptor subunit alpha-2 antibody-drug conjugates and uses thereof
WO2025106658A1 (en) * 2023-11-15 2025-05-22 Exelixis, Inc. 5t4 antibody drug conjugates and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2644906C (en) * 2006-03-06 2016-05-10 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2015081282A1 (en) * 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP4257134A3 (en) * 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
CA3082912A1 (en) * 2017-12-11 2019-06-20 Triphase Accelerator U.S. Corporation Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024041959A5 (https=)
US12269812B2 (en) PD-1/PD-L1 inhibitors
JP7273172B2 (ja) Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
US10899735B2 (en) PD-1/PD-L1 inhibitors
JP2024026363A (ja) Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
KR20230008723A (ko) 전하 변이체 링커
EP3727463A1 (en) Pyrrolobenzodiazepine antibody conjugates
ES2973303T3 (es) Formas sólidas de un modulador del receptor tipo toll
ES2992125T3 (es) Formas sólidas de un modulador de los receptores tipo Toll
RU2755899C2 (ru) Нелинейные саморасщепляющиеся линкеры и их конъюгаты
KR20170128256A (ko) Cd48 항체 및 이의 접합체
EP2991677A1 (en) Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
WO2022155518A1 (en) Immunomodulatory antibody-drug conjugates
US20250186592A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
US20250009890A1 (en) Trans-cyclooctene-modified bispecific antibodies
EP3585789A1 (en) Inhibitors of bruton's tyrosine kinase
EP4422693A1 (en) Trans-cyclooctene conjugates
JPH02191300A (ja) 抗体―薬物抱合体
WO2025207828A1 (en) Nanocomposition comprising modified exatecan and use thereof
US20230301981A1 (en) Tlr7/8 antagonists and uses thereof
JP2026508188A (ja) トランス－シクロオクテンコンジュゲート
WO2024229427A1 (en) Tetrazine-based targeting agents for in vivo delivery of a payload
WO2021022258A1 (en) Tetracycline compounds for the treatment of hematological cancers